15-min delayed · Sep 4, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 7 firms covering Integra LifeSciences Holdings, 0 rate it Buy or better, 6 sit at Hold, and 1 rate it Sell or worse, a hold consensus. Targets span $13.00 to $19.00, a moderate spread. The average target of $17.83 sits 7% above the current $16.71. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.80 next quarter toward $2.61 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 ratings
Hold
Strong Buy00%
Buy00%
Hold686%
Sell114%
Strong Sell00%
Based on 7 analysts giving stock ratings to Integra LifeSciences Holdings.
As of Sep, 0 of 7 firms rate IART a Buy (6 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
IART EPS & revenue forecast
EPS · NEXT QUARTER
$0.80
Range $0.74 – $0.89 · 11 analysts · -3% YoY
Next period, 11 analysts expect Integra LifeSciences Holdings to earn $0.80 a share (range $0.74 – $0.89), versus $0.83 a year earlier. Full-year consensus is $2.46, growing to $2.61 the year after.
REVENUE · NEXT QUARTER
$447.4M
Range $441.9M – $453.9M · 11 analysts · +3% YoY
Revenue is expected to reach $447.4M (range $441.9M – $453.9M), +2.9% year-over-year. Full-year consensus is $1.7B, rising to $1.7B next year.
Top analysts covering Integra LifeSciences Holdings
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IART.
#1
JB
Jayson Bedford
Raymond James · Rank #196
Hold
No targeton IART
Overall win rate
42%
+ Follow
#2
David Turkaly
JMP Securities · Rank #346
Buy
$25.00+49.6% to target
Overall win rate
33%
+ Follow
#3
Joanne Wuensch
Citigroup
Hold
$19.00+13.7% to target
Coverage
—
+ Follow
#4
RM
Ravi Misra
Truist Securities
Hold
$19.00+13.7% to target
Coverage
—
+ Follow
#5
David Toung
Argus Research
Buy
$25.00+49.6% to target
Coverage
—
+ Follow
IART stock forecast FAQ
What is IART's average 12-month price target?+
The 6 analysts with a live target average $17.83 for Integra LifeSciences Holdings over the next 12 months, ranging from a $19.00 high to a $13.00 low.
Is IART stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 7 analyst ratings, 0 are Buy or Strong Buy, 6 are Hold, and 1 are Sell or Strong Sell.
What are the highest and lowest price targets for IART?+
The Street-high target is $19.00 (UBS), and the Street-low is $13.00 (JP Morgan). The average of all 6 active targets is $17.83.
How many Wall Street analysts cover IART?+
7 analysts have an active rating on Integra LifeSciences Holdings, and 6 firms carry a live 12-month price target.
Who is the most accurate analyst covering IART?+
Among analysts who currently cover IART, Jayson Bedford of Raymond James has the strongest overall Quantellect track record (Rank #196). Their current call is Hold.
What is Integra LifeSciences Holdings's projected EPS for next quarter?+
The consensus estimate is $0.80 per share (range $0.74 – $0.89) across 11 analysts. Full-year EPS is projected at $2.46, rising to $2.61 the following year.
How much revenue is Integra LifeSciences Holdings expected to report next quarter?+
Consensus revenue is $447.4M (range $441.9M – $453.9M). Full-year revenue is projected at $1.7B, growing to $1.7B next year.
Have analysts been upgrading or downgrading IART lately?+
As of Sep, 0 of 7 firms rate IART a Buy (6 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IART calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
UBS
BMO Capital
